JP2004501899A5 - - Google Patents

Download PDF

Info

Publication number
JP2004501899A5
JP2004501899A5 JP2002505374A JP2002505374A JP2004501899A5 JP 2004501899 A5 JP2004501899 A5 JP 2004501899A5 JP 2002505374 A JP2002505374 A JP 2002505374A JP 2002505374 A JP2002505374 A JP 2002505374A JP 2004501899 A5 JP2004501899 A5 JP 2004501899A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002505374A
Other versions
JP2004501899A (ja
JP3935071B2 (ja
Filing date
Publication date
Priority claimed from GBGB0015601.8A external-priority patent/GB0015601D0/en
Application filed filed Critical
Publication of JP2004501899A publication Critical patent/JP2004501899A/ja
Publication of JP2004501899A5 publication Critical patent/JP2004501899A5/ja
Application granted granted Critical
Publication of JP3935071B2 publication Critical patent/JP3935071B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002505374A 2000-06-26 2001-06-21 融合アゼピン誘導体および抗利尿剤としての使用 Expired - Fee Related JP3935071B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015601.8A GB0015601D0 (en) 2000-06-26 2000-06-26 Novel antidiuretic agents
PCT/GB2001/002737 WO2002000626A1 (en) 2000-06-26 2001-06-21 Fused azepine derivatives and their use as antidiuretic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005011930A Division JP2005104990A (ja) 2000-06-26 2005-01-19 融合アゼピン誘導体および抗利尿剤としての使用

Publications (3)

Publication Number Publication Date
JP2004501899A JP2004501899A (ja) 2004-01-22
JP2004501899A5 true JP2004501899A5 (ja) 2005-12-22
JP3935071B2 JP3935071B2 (ja) 2007-06-20

Family

ID=9894399

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2002505374A Expired - Fee Related JP3935071B2 (ja) 2000-06-26 2001-06-21 融合アゼピン誘導体および抗利尿剤としての使用
JP2005011930A Withdrawn JP2005104990A (ja) 2000-06-26 2005-01-19 融合アゼピン誘導体および抗利尿剤としての使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2005011930A Withdrawn JP2005104990A (ja) 2000-06-26 2005-01-19 融合アゼピン誘導体および抗利尿剤としての使用

Country Status (22)

Country Link
US (1) US7176195B2 (ja)
EP (1) EP1294698B1 (ja)
JP (2) JP3935071B2 (ja)
KR (1) KR100805808B1 (ja)
CN (1) CN1308313C (ja)
AT (1) ATE368650T1 (ja)
AU (2) AU2001274290B9 (ja)
CA (1) CA2412555A1 (ja)
CZ (1) CZ304037B6 (ja)
DE (1) DE60129697T2 (ja)
GB (1) GB0015601D0 (ja)
HK (1) HK1059780A1 (ja)
HU (1) HU229315B1 (ja)
IL (1) IL153358A0 (ja)
MX (1) MXPA02012779A (ja)
NO (1) NO324217B1 (ja)
NZ (1) NZ523066A (ja)
PL (1) PL359187A1 (ja)
RU (1) RU2269517C2 (ja)
UA (1) UA73177C2 (ja)
WO (1) WO2002000626A1 (ja)
ZA (1) ZA200300403B (ja)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138393B2 (en) 1998-07-24 2006-11-21 Wyeth Biologically active vasopressin agonist metabolites
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
EP2426122A1 (en) * 2002-10-24 2012-03-07 Merck Patent GmbH Methylene urea derivative as RAF kinasse inhibitors
CA2511970C (en) 2003-01-14 2012-06-26 Cytokinetics, Inc. Urea derivatives useful in the treatment of heart failure
ATE467616T1 (de) * 2003-04-11 2010-05-15 High Point Pharmaceuticals Llc Verbindungen mit aktivität an der 11beta- hydroxasteroiddehydrogenase
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
US7255726B2 (en) * 2003-05-02 2007-08-14 Worcester Polytechnic Institute Composite gas separation modules having high Tamman temperature intermediate layers
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists
ES2260563T3 (es) * 2003-11-13 2006-11-01 Ferring B.V. Paquete de blister y forma farmaceutica solida para ello.
US8110595B2 (en) 2004-06-17 2012-02-07 Cytokinetics, Inc. Ureas and their use in the treatment of heart failure
US7176222B2 (en) 2004-07-27 2007-02-13 Cytokinetics, Inc. Syntheses of ureas
EP1627876A1 (en) * 2004-08-20 2006-02-22 Ferring B.V. Heterocyclic condensed compounds useful as antidiuretic agents
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
JP4943858B2 (ja) * 2004-11-17 2012-05-30 キッセイ薬品工業株式会社 芳香族アミド誘導体、それを含有する医薬組成物およびそれらの医薬用途
US7538223B2 (en) 2005-08-04 2009-05-26 Cytokinetics, Inc. Compounds, compositions and methods
US7825120B2 (en) 2005-12-15 2010-11-02 Cytokinetics, Inc. Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas
AR058347A1 (es) 2005-12-15 2008-01-30 Cytokinetics Inc Entidades quimias composiciones y metodos
US7718657B2 (en) 2005-12-16 2010-05-18 Cytokinetics, Inc. Certain indanyl urea modulators of the cardiac sarcomere
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
SE528446C2 (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
BRPI0811204A8 (pt) * 2007-05-10 2015-09-22 Bristol Myers Squibb Co Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
EP2197532A1 (en) 2007-08-06 2010-06-23 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
ES2596435T3 (es) * 2008-05-21 2017-01-09 Ferring B.V. Desmopresina bucodispersable para aumentar el periodo inicial de sueño ininterrumpido por nicturia
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
GB201005623D0 (en) * 2010-04-01 2010-05-19 Vantia Ltd New polymorph
EP2681196B1 (en) * 2011-03-04 2015-09-09 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
GB201105537D0 (en) * 2011-03-31 2011-05-18 Vantia Ltd New process
CN103159641A (zh) * 2011-12-14 2013-06-19 天津泰普药品科技发展有限公司 托伐普坦中间体2-甲酸-5-(2-甲基苯甲酰氨基)甲苯的制备方法
RU2480468C1 (ru) * 2012-02-16 2013-04-27 Открытое Акционерное Общество "Международная Научно-Технологическая Корпорация" КРИСТАЛЛИЧЕСКАЯ МОДИФИКАЦИЯ ПАРА-МЕТОКСИАНИЛИДА 6-ГИДРОКСИ-4-ОКСО-2,4-ДИГИДРО-1Н-ПИРРОЛО[3,2,1-ij]ХИНОЛИН-5-КАРБОНОВОЙ КИСЛОТЫ
CN103373960B (zh) * 2012-04-24 2017-03-01 江苏康缘药业股份有限公司 一种托伐普坦中间体及其制备方法
WO2020154581A1 (en) * 2019-01-24 2020-07-30 Assia Chemical Industries Ltd Solid state forms of fedovapagon-salicyclic acid co-crystal

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
ATE239710T1 (de) * 1994-06-15 2003-05-15 Otsuka Pharma Co Ltd Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
PT1000059E (pt) * 1997-07-30 2004-12-31 Wyeth Corp Agonistas triciclicos de vasopressina
JP4338305B2 (ja) 1997-07-30 2009-10-07 ワイス 三環系バソプレシンアゴニスト
GB2355454A (en) * 1999-10-20 2001-04-25 Ferring Bv Antidiuretic agents
GB0000079D0 (en) 2000-01-05 2000-02-23 Ferring Bv Novel antidiuretic agents

Similar Documents

Publication Publication Date Title
BE2022C531I2 (ja)
BE2022C502I2 (ja)
BE2022C547I2 (ja)
BE2017C055I2 (ja)
BE2017C051I2 (ja)
BE2017C032I2 (ja)
BE2016C051I2 (ja)
BE2015C046I2 (ja)
BE2014C036I2 (ja)
BE2014C026I2 (ja)
BE2014C004I2 (ja)
BE2014C006I2 (ja)
BE2017C050I2 (ja)
BE2011C034I2 (ja)
BE2007C047I2 (ja)
AU2002307149A8 (ja)
BE2016C021I2 (ja)
BE2014C008I2 (ja)
CH1379220H1 (ja)
BRPI0204884B1 (ja)
BE2017C059I2 (ja)
BRPI0101486B8 (ja)
BE2012C051I2 (ja)
JP2002229778A5 (ja)
AU2000280389A8 (ja)